Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades. The findings could lead to a better ...
Predicting Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery: Real-World Data From the International GOSAFE Study Between July 2016 and April 2019, 91 ...
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study Supported by the NIH/NCI ...
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...
Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study that assessed ctDNA in the blood of patients with BRAF wild-type (BRAF ...
In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating ...
CHICAGO -- First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results